ImpediMed Limited is the world leader in the development and distribution of medical devices employing bioimpedance spectroscopy (BIS) technologies for use in the noninvasive clinical assessment and monitoring of fluid status. ImpediMed’s primary product range consists of a number of medical devices that aid surgeons, oncologists, therapists and radiation oncologists in the clinical assessment of patients for the potential onset of secondary lymphoedema. Pre-operative clinical assessment in cancer survivors, before the onset of symptoms, may prevent the condition from becoming a lifelong management issue and thus improve the quality of life of the cancer survivor. ImpediMed had the first medical device with an FDA clearance in the United States to aid health care professionals in the clinical assessment of secondary lymphoedema of the arm and leg in female and male cancer patients.
Location: United States, California, Carlsbad
Employees: 51-200
Phone: +1 760-585-2100
Total raised: $72.94M
Founded date: 1999
Investors 1
| Date | Name | Website |
| 09.02.2025 | SWK Holdin... | swkhold.co... |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 10.02.2025 | - | $15M | - |
| 06.05.2020 | - | $1.14M | - |
| 23.03.2016 | - | $56.8M | - |
Mentions in press and media 6
| Date | Title | Description |
| 11.02.2025 | ImpediMed Secures $15 Million to Propel Growth in Lymphedema Management | In the fast-paced world of medical technology, securing funding is akin to catching lightning in a bottle. ImpediMed, a trailblazer in fluid and body composition monitoring, has just captured that lightning. The Carlsbad, California-based c... |
| 10.02.2025 | ImpediMed Raises $15M in Growth Funding | ImpediMed, a Carlsbad, CA-based company which specializes in medical technologies to clinically monitor and manage fluid and body composition, raised $15M in growth funding. Backers included SWK Holdings (NASDAQ:SWKH). The company intends t... |
| 10.02.2025 | ImpediMed: $15 Million In Growth Capital Raised | ImpediMed, a leader in medical technologies for clinically monitoring and managing fluid and body composition, announced an agreement for a five-year $15 million growth capital facility with SWK Holdings, a life science-focused specialty fi... |
| 02.02.2022 | New Data Show Statistically Significant Reduction In Chronic Cancer-Related Lymphedema With Early Detection Using ImpediMed L-Dex Technology And Intervention | Lymphatic Research and Biology Publishes Data on PREVENT, the Largest Randomized Trial to Assess Lymphedema Prevention L-Dex Technology Provides a New Standard Approach for Prevention of Cancer-Related Lymphedema ImpediMed Limited a global ... |
| 23.03.2016 | ImpediMed Raises $56.8M In Private Placement | ImpediMed, a developer of medical devices used to measure, monitor, and manage fluid status in patients, said Tuesday that it has raised $56.8M in a private placement. The company--which is based in Australia, but has its U.S. headquarters ... |
| 15.01.2009 | The Aussies come to Silicon Valley: Six companies compete for best start-up | Six Australian companies competed today for the best start-up at The Australian Innovation Shoot Out event this morning in Menlo Park, Calif. I was on hand to moderate and was impressed with the quality of the six finalists. The event, spon... |